Company intelligence / Profile preview

TroBio Therapeutics

Sydney, New South Wales, Australia

Ownership: Private
Development stage: Other

Overview

TroBio is developing anti-tropomyosin drugs that target cancer cell resistance mechanisms to chemotherapy. The company's approach focuses on blocking the force-generating machinery cancer cells use to overcome anti-microtubule chemotherapy. Research has shown that cancer cells activate a cortical tension mechanism to stabilize microtubules during cell division, allowing them to resist chemotherapy effects.

Therapeutic areas: Oncology
Modalities: Small molecule
Industry: Biotech

Partnerships

University of New South WalesUniversity of Technology SydneyICP Firefly

Beyond the preview

Go deeper on TroBio Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TroBio Therapeutics.

Explore the full profile